Baidu
map

Meta分析软件—RevMan5.0使用中文指南(6)

2013-05-26 MedSci MedSci原创

PART 6 – Finishing the review 第六章 完成综述 Summary of findings tables  第一节 结果总结表 Adding an appendix  第二节 增加附录 Validating a review 第三节 检查综述 Submitting a review for editorial appro

PART 6 – Finishing the review
第六章 完成综述

Summary of findings tables 
第一节 结果总结表

Adding an appendix 
第二节 增加附录

Validating a review
第三节 检查综述

Submitting a review for editorial approval 
第四节 提交综述给编辑审核

Summary of findings tables 
第一节 结果总结表

When your review is complete, summary of findings tables can be added. For more information on how to complete a summary of findings table, see the Cochrane Handbook for Systematic Reviews of Interventions, available from the Help menu. 
当你的综述完成后,就可以添加结果总结表(summary of findings tables)了。关于如何添加结果总结表(summary of findings tables),参见帮助(Help)菜单下的“Cochrane Handbook for Systematic Reviews of Interventions”。
 
1. In the outline pane, use the key icon   to expand the Tables heading, and select Summary of findings. 
1 在大纲面板(outline pane),点击“Tables”旁边的钥匙图标,选择“Summary of findings”。

2. Click the Add Summary of Findings Table   button on the outline pane toolbar. This will open the New Summary of Findings Table Wizard. 
2 点击大纲面板工具栏(outline pane toolbar)上的“ Add Summary of Findings Table”按钮。这将打开“ New Summary of Findings Table Wizard”对话框。

3. There are three options for adding a summary of findings table to your review: 
3 这里有3种选择可以在你的综述中添加结果总结表(summary of findings tables):

•  Import a complete summary of findings table from GRADEprofiler (a separate software program designed to produce these tables). 
   从GRADEprofiler(一个独立的制作这些表的软件)导入完整的结果总结表(summary of findings tables)。

•  Use a template to create a summary of findings table in RevMan. 
   使用RevMan中的模板创建结果总结表(summary of findings tables)。

•  Open a blank table to create your own summary of findings table. 
   打开一个空白表来创建你自己的结果总结表(summary of findings tables)。

For this tutorial, select Import the template file included with RevMan to edit the table in RevMan. Click Next. 
对于本例来说,选择“Import the template file included with RevMan to edit the table in RevMan”,点击下一步(Next)。

4. RevMan will display a preview of the table template. Click Finish. 
4 RevMan将预览模板表。点击完成(Finish)。

5. The template summary of findings table will be added to your review. You can edit this template by typing directly into the table. 
5 结果总结表(summary of findings tables)的模板就被添加到你的综述中了。你可以在表中直接输入来编辑模板。

Adding an appendix 
第二节 增加附录

You can include more detailed information that is not essential to the main body of your review in an appendix, such as detailed search strategies or statistical methods. 
你可以在你的综述的正文后的附录中添加更多的必要细节信息,比如检索策略或统计方法。

1. In the outline pane, select the Appendices heading (the last heading on the list). 
1 在大纲面板(outline pane),选择“Appendices”(位于列表最后)。

2. Click the Add Appendix button   on the outline pane toolbar. This will open the New Appendix Wizard. 
2 点击大纲面板工具栏(outline pane toolbar)上的“Add Appendix”按钮,这将弹出一个“New Appendix Wizard”对话框。

3. Enter the Title ‘Detailed search strategies’. 
3 输入标题(Title)“Detailed search strategies”。

4. Click Finish. In the content pane, the Appendices section will open and your appendix title will be shown. You can now enter text in the appendix. 
4 点击完成(Finish)。在内容面板(content pane),附录(Appendices)部分出现,并显示附录标题。现在,你可以在附录中输入信息。

Validating a review 
第三节 检查综述

Before publication, every review should be validated to make sure all sections have been completed and meet the requirements of The Cochrane Collaboration. 
在发表以前,所有的综述都应该先检查一遍,以保证每个部分都完成,且符合Cochrane协作网的要求。

1. From the Tools menu, select Validate as You Type, or click the Validate as You Type   button on the toolbar. In the outline pane, any sections with problems identified will be underlined. 
1 在工具(Tools)菜单,选择“Validate as You Type”或者点击工具栏上的“Validate as You Type”按钮。在大纲面板(outline pane),如果一个部分有问题,下划线会出现。

2. Hover the mouse over a section underlined in red. A Validation error message will appear. Validation errors must be corrected before publication. 
2 将鼠标停在红色下划线部分上。一个检查错误(Validation error)消息出现。在发表前,检查错误(Validation error)必须被修正。

3. Hover the mouse over a section underlined in blue. A Validation warning message will appear. It is not compulsory to correct Validation warnings. 
3 将鼠标停在蓝色下划线部分上。一个检查警告(Validation warning)消息出现。这个错误不是必须被修正的。

4. From the File menu, select Reports, and then Validation report. A report will be displayed listing all the Validation errors and Validation warnings. You can choose to copy, print or save this report. 

4 在文件(File)菜单,选择报告(Reports),在选择检查报告(Validation report)。一份包含所有的检查错误(Validation error)和检查警告(Validation warning)的报告将呈现。你可以复制、打印或保存这份报告。

5. Click OK. 
5 点击“OK”。

Submitting a review for editorial approval 
第四节 提交综述给编辑审核

When you have completed all the remaining sections of the review, including the Abstract and Plain language summary, you will need to submit the review to your Cochrane Review Group for editorial approval. You can select this option when checking the review into the Archie database, and your Review Group Co-ordinator will receive an automatic message advising that the review is ready. 
当你完成综述中包括摘要(Abstract)和平白总结(Plain language summary)的剩余部分后,你需要把这份综述提交给你的Cochrane评价小组(Cochrane Review Group)进行编辑审核。你可以在把综述提交给Archie数据库时进行此项选择,你评价小组协作者(Review Group Co-ordinator)会自动收到消息提示有新综述需要审核。

You will not be able to access your review during the editorial process.
在编辑审核阶段,你不能再对你的综述进行修改。 

When you have made all the changes requested and the review is ready to publish, you and all your co-authors will need to sign the Licence for Publication Form, available from the File menu under Reports. 
当你修改完所有不合规范的地方后,你就可以发表了,这是,你和你的共同作者需要在“Licence for Publication Form”上签名,这个表格可在文件(File)才的下的报告(Reports)中获得。

Note: This tutorial has been prepared by the Australasian Cochrane Centre, with assistance from the Thai Cochrane Network and the Information Management System team. 
注意:这个教程由主要由澳洲Cochrane中心(Australasian Cochrane Centre)编写,并且获得了泰国Cochrane网络(Thai Cochrane Network)和信息管理系统小组( Information Management System team)的帮助。

Meta分析软件—RevMan5.0使用中文指南(1)
Meta分析软件—RevMan5.0使用中文指南(2)
Meta分析软件—RevMan5.0使用中文指南(3)
Meta分析软件—RevMan5.0使用中文指南(4)
Meta分析软件—RevMan5.0使用中文指南(5)
Meta分析软件—RevMan5.0使用中文指南(6)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=54605, encodeId=2a535460578, content=好丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160108/IMG568F572F2085A8382.jpg, createdBy=6d891676296, createdName=曹真, createdTime=Fri Jan 08 14:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895668, encodeId=d693189566872, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 14 04:26:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887350, encodeId=0b95188e3500b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Sep 17 23:26:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250170, encodeId=e95e12501e06b, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon May 27 00:26:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2016-01-08 曹真

    好丰富

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=54605, encodeId=2a535460578, content=好丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160108/IMG568F572F2085A8382.jpg, createdBy=6d891676296, createdName=曹真, createdTime=Fri Jan 08 14:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895668, encodeId=d693189566872, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 14 04:26:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887350, encodeId=0b95188e3500b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Sep 17 23:26:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250170, encodeId=e95e12501e06b, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon May 27 00:26:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-10-14 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=54605, encodeId=2a535460578, content=好丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160108/IMG568F572F2085A8382.jpg, createdBy=6d891676296, createdName=曹真, createdTime=Fri Jan 08 14:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895668, encodeId=d693189566872, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 14 04:26:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887350, encodeId=0b95188e3500b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Sep 17 23:26:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250170, encodeId=e95e12501e06b, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon May 27 00:26:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-09-17 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=54605, encodeId=2a535460578, content=好丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160108/IMG568F572F2085A8382.jpg, createdBy=6d891676296, createdName=曹真, createdTime=Fri Jan 08 14:59:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895668, encodeId=d693189566872, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Oct 14 04:26:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887350, encodeId=0b95188e3500b, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Sep 17 23:26:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250170, encodeId=e95e12501e06b, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Mon May 27 00:26:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]

相关资讯

Meta分析软件—RevMan5.0使用中文指南(4)

PART 4 - Tables  第四章 表格 Characteristics of included studies table 第一节 纳入研究特征表 Risk of bias table 第二节 偏倚风险表 Characteristics of excluded studies 第三节 排除研究特征表 Additional tables 

Meta分析软件—RevMan5.0使用中文指南(2)

PART 2 – Working with text  第二章 编辑文本 Adding text to a review 第一节 在综述中添加文本 Formatting text 第二节 文本格式 Making changes to headings 第三节 改变标题 Adding notes  第四节 添加笔记 Tracking cha

Meta分析软件—RevMan5.0使用中文指南(3)

PART 3 – Adding studies and references 第三章 添加研究和参考文献 Adding studies to a review 第一节 在综述中添加研究 Adding references to a study 第二节 给研究添加参考文献 Editing an existing reference  第三节 编辑已有的参考文献

微创人工全髋关节置换术与传统置换术临床疗效的Meta分析

  日前,天津医院骨科研究所、天津医科大学总医院骨科生物力学实验室共同发表论文,旨在通过检索和分析国内外相关文献,应用Meta分析的方法评价微创和传统人工全髋关节置换术(total hip arthroplasty,THA)的临床疗效。研究指出,尽管微创THA较传统THA的切口小、出血量少、术后疼痛轻,但术后功能的恢复、手术时间、输血量和并发症的发生率与传统THA相当。需进一步

Meta分析软件—RevMan5.0使用中文指南(1)

Review Manager 5 Tutorial  RevMan5.0使用指南 前言 Welcome to the RevMan Tutorial. This tutorial is designed to give Cochrane review authors an introduction to the process of writing a Coch

Meta分析软件—RevMan5.0使用中文指南(5)

PART 5 - Data and analyses 第五章 数据与分析 Adding comparisons and outcomes  第一节 增加比较和结局 Entering dichotomous data 第二节 输入二分类变量数据 Changing outcome properties  第三节 改变结局属性 Adding subgr

Baidu
map
Baidu
map
Baidu
map